Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.
Boisteau E, Lespagnol A, De Tayrac M, Corre S, Perrot A, Rioux-Leclercq N, Martin-Lannerée S, Artru P, Chalabreysse P, Poureau PG, Doucet L, Coupez D, Bennouna J, Bossard C, Coriat R, Beuvon F, Bauguion L, Leclair F, Chautard R, Lecomte T, Guyetant S, Desgrippes R, Grasset D, Lhostis H, Bouhier-Leporrier K, Bibeau F, Edeline J, Galibert MD, Lièvre A. Boisteau E, et al. Among authors: desgrippes r. Clin Res Hepatol Gastroenterol. 2022 May;46(5):101888. doi: 10.1016/j.clinre.2022.101888. Epub 2022 Feb 18. Clin Res Hepatol Gastroenterol. 2022. PMID: 35189426 Free article.
Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma.
Blay C, Chiforeanu DC, Boucher E, Cabillic F, Desgrippes R, Leconte B, Perrin C, Manfredi S, Audrain O, Meunier B, Edeline J. Blay C, et al. Among authors: desgrippes r. Acta Oncol. 2015 Nov;54(10):1833-5. doi: 10.3109/0284186X.2015.1011757. Epub 2015 Mar 10. Acta Oncol. 2015. PMID: 25753188 Free article. No abstract available.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C; PRODIGE 59-FFCD 1707-DURIGAST Investigators/Collaborators. Tougeron D, et al. JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0207. Online ahead of print. JAMA Oncol. 2024. PMID: 38573643
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, Idbaih A, Ursu R, Di Stefano AL, Zalcman G, Aparicio T; GCO-002 CACOVID-19 collaborators/investigators. Lièvre A, et al. Eur J Cancer. 2020 Dec;141:62-81. doi: 10.1016/j.ejca.2020.09.035. Epub 2020 Oct 8. Eur J Cancer. 2020. PMID: 33129039 Free PMC article.
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V, Monterymard C, Lorgis V, Thuillier F, Baudin E, Scoazec JY, Lepage C, Desgrippes R. Hadoux J, et al. Among authors: desgrippes r. Dig Liver Dis. 2021 Jul;53(7):824-829. doi: 10.1016/j.dld.2021.04.016. Epub 2021 May 12. Dig Liver Dis. 2021. PMID: 33994125 Clinical Trial.
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.
Manfredi S, Dior M, Bouche O, Barbier E, Hautefeuille V, Guillet M, Turpin J, Bourgeois V, Helene DO, Desgrippes R, Audemar F, Molin Y, Locher C, Chatellier T, Lecomte T, Baize N, Lecaille C, Spaeth D, Goujon G, Lepage C, Tougeron D; Metestomac Investigators/Collaborators. Manfredi S, et al. Among authors: desgrippes r. Cancer Med. 2023 Mar;12(5):5341-5351. doi: 10.1002/cam4.5354. Epub 2022 Nov 16. Cancer Med. 2023. PMID: 36394147 Free PMC article.
Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P, Tougeron D, Allignet B, Cohen R, Sefrioui D, Gallet B, Dumont F, Guimbaud R, Alouani E, Passot G, Desolneux G, Ghiringhelli F, Marchal F, Mourthadhoi F, Coriat R, Desgrippes R, Locher C, Goujon G, Des Guetz G, Aparicio T, Paubelle E, Dupré A, de la Fouchardière C. Marolleau P, et al. Among authors: desgrippes r. Int J Cancer. 2023 Oct 1;153(7):1376-1385. doi: 10.1002/ijc.34636. Epub 2023 Jul 5. Int J Cancer. 2023. PMID: 37403609
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
De La Fouchardière C, Malka D, Cropet C, Chabaud S, Raimbourg J, Botsen D, Launay S, Evesque L, Vienot A, Perrier H, Jary M, Rinaldi Y, Coutzac C, Bachet JB, Neuzillet C, Williet N, Desgrippes R, Grainville T, Aparicio T, Peytier A, Lecomte T, Roth GS, Thirot-Bidault A, Lachaux N, Bouché O, Ghiringhelli F. De La Fouchardière C, et al. Among authors: desgrippes r. J Clin Oncol. 2024 Mar 20;42(9):1055-1066. doi: 10.1200/JCO.23.00795. Epub 2024 Jan 17. J Clin Oncol. 2024. PMID: 38232341 Clinical Trial.
16 results